Table 3.

Overall and subgroup analysis for relation between XRCC1 rs25487 and treatment response.

Comparison	Group	Subgroup	No. Patients	No. Study	OR	95% CI	P value	Heterogeneity	Effect model
AA vs GG	Overall		1396	19	0.89	0.53–1.49	0.658	61.0%	Random
	Cancer	Esophageal cancer	345	6	0.65	0.15–2.73	0.554	80.9%	Random
		Rectal cancer	383	6	0.63	0.39–1.01	0.056	0.0%	Fixed
	Cutoff	SD+PD	737	8	0.97	0.41–2.30	0.626	67.2%	Random
		Grade ≥3	325	5	0.52	0.31–0.86	0.012	0.0%	Fixed
	Treatment	RCT	688	12	0.69	0.47–1.01	0.059	20.2%	Fixed
		RT	557	5	1.30	0.36–4.63	0.687	84.7%	Random
GA vs GG	Overall		1843	19	1.14	0.93–1.40	0.221	19.1%	Fixed
	Cancer	Esophageal cancer	375	6	0.50	0.30–0.83	0.008	15.5%	Fixed
		Rectal cancer	537	6	1.41	0.99–2.01	0.059	0.0%	Fixed
	Cutoff	SD+PD	983	8	1.06	0.81–1.38	0.673	48.3%	Fixed
		Grade ≥3	388	5	1.20	0.78–1.86	0.407	6.1%	Fixed
	Treatment	RCT	945	12	1.19	0.90–1.59	0.222	0.0%	Fixed
		RT	683	5	0.92	0.46–1.86	0.819	60.7%	Random
GA+AA vs GG	Overall		2580	24	1.08	0.90–1.29	0.401	48.8%	Fixed
	Cancer	Esophageal cancer	573	7	0.71	0.29–1.77	0.464	76.6%	Random
		Rectal cancer	742	7	1.05	0.77–1.44	0.743	0.0%	Fixed
	Cutoff	SD+PD	1223	9	0.85	0.51–1.43	0.536	68.4%	Random
		Grade ≥3	586	6	0.85	0.59–1.21	0.360	0.0%	Fixed
	Treatment	RCT	1393	16	1.03	0.81–1.30	0.817	14.0%	Fixed
		RT	963	6	0.99	0.46–2.14	0.975	78.4%	Random

RCT, radio-chemotherapy; RT, radiotherapy; SD, stable disease; PD, progressive disease. The bold values mean that they are statistically significant.